| Titre : |
1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial |
| Titre traduit : |
(Efficacité d'un traitement à la buprénorphine de 1 an, associé à un soutien social, pour prévenir la rechute d'héroïnomanes en Suéde : un essai randomisé contre placebo.) |
| Type de document : |
Périodique |
| Auteurs : |
J. KAKKO ; K. D. SVANBORG ; M. J. KREEK ; M. HEILIG |
| Année de publication : |
2003 |
| Importance : |
662-668 |
| Présentation : |
graph. ; tabl. |
| Note générale : |
Lancet (The), 2003, 361, 662-668
|
| Langues : |
Anglais (eng) |
| Mots-clés : |
Thésaurus TOXIBASE
SUBSTITUTION ; BUPRENORPHINE ; RETENTION ; EFFICACITE ; RECHUTE
Thésaurus Géographique
SUEDE
|
| Discipline : |
TRA Traitement et prise en charge / Treatment and care |
| Résumé : |
Background: The partial opiate-receptor agonist buprenorphine has been suggested for treatment of heroin dependence, but there are few long-term and placebo-controlled studies of its effectiveness. We aimed to assess the 1-year efficacy of buprenorphine in combination with intensive psychosocial therapy for treatment of heroin dependence. Methods: 40 individuals aged older than 20 years, who met DSM-IV criteria for opiate dependence for at least 1 year, but did not fulfil Swedish legal criteria for methadone maintenance treatment were randomly allocated either to daily buprenorphine (fixed dose 16 mg sublingually for 12 months; supervised daily administration for a least 6 months, possible take-home doses thereafter) or a tapered 6 day regimen of buprenorphine, thereafter followed by placebo. All patients participated in cognitive-behavioural group therapy to prevent relapse, received weekly individual counselling sessions, and submitted thrice weekly supervised urine samples for analysis to detect illicit drug use. Our primary endpoint was 1-year retention in treatment and analysis was by intention to treat. Findings: 1-year retention in treatment was 75% and 0% in the buprenorphine and placebo groups, respectively (p=00001; risk ratio 58,7 [95% CI 7.4-467.4]). Urine screens were about 75% negative for illicit opiates, central stimulants, cannabinoids, and benzodiazepines in the patients remaining in treatment. Interpretation: The combination of buprenorphine and intensive psychosociaf treatment is safe and highly efficacious, and should be added to the treatment options available for individuals who are dependent on heroin. (Author' s abstract) |
| Domaine : |
Drogues illicites / Illicit drugs |
| Refs biblio. : |
30 |
| Affiliation : |
Div. of Psychiatry, NEUROTEC, Karolinska Institute, Huddinge Univ. Hospital, S-141 86 Stockholm.
Suède. Sweden. |
| Numéro Toxibase : |
206790 |
| Centre Emetteur : |
02 Coordonnateur |
| Permalink : |
https://bdoc.ofdt.fr/index.php?lvl=notice_display&id=20771 |
|
1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial
Accueil
